Aribiolab아리바이오랩
261780 · KOSDAQ · ₩261780 · 아리바이오랩
₩3,400▼ ₩185 (5.16%)End-of-day · Oct 27, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 92.5% | 90.7% | 93.5% | 88.3% | 89.4% | 100.0% |
| Operating margin | −7,491.7% | −8,997.2% | −2,076.4% | −2,182.5% | −3,604.4% | −1,216.9% |
| Net margin | −8,616.3% | −10,115.3% | −2,735.2% | −594.8% | −3,741.4% | −3,684.0% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | +9.2% | −57.2% | +26.0% | +63.9% | −64.1% | — |
| Operating income growth | +9.1% | −85.4% | −19.9% | +0.8% | −6.3% | — |
| Net income growth | +7.0% | −58.3% | −479.5% | +73.9% | +63.5% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | −137.2% | −81.1% | −32.1% | −5.1% | −18.4% | −46.5% |
| Return on assets | −58.6% | −41.7% | −22.0% | −3.3% | −10.6% | −28.2% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 113.8% | 151.1% | 70.4% | 27.4% | 83.0% | 64.9% |
| Net debt to equity | — | — | −128.0% | −98.6% | 62.5% | 42.3% |
| Current ratio | 191.7% | 166.1% | 463.8% | 5,244.0% | 219.9% | 250.3% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Aribiolab / 아리바이오랩 / 261780 / KRX:261780
Source: KRX statistical information